Delivery Vehicles for Prenatal Calcium Supplementation

Sponsor
The Hospital for Sick Children (Other)
Overall Status
Completed
CT.gov ID
NCT01676636
Collaborator
The Sprinkles Global Health Initiative (Other), International Centre for Diarrhoeal Disease Research, Bangladesh (Other)
149
2
5
74.5
15

Study Details

Study Description

Brief Summary

The SickKids-led research team is currently developing a prenatal micronutrient powder that will contain calcium, iron, and folic acid with different absorption characteristics. Once the powder is developed, it can be incorporated into various oral delivery vehicles. The overall effectiveness of a micronutrient program is highly dependent on the acceptance and regular consumption of supplements (i.e., adherence) by the targeted users. This is a study of the preference, acceptability, and palatability of 4 alternative delivery vehicles for the innovative prenatal multiple micronutrient supplement: traditional tablets, oral disintegrating tablets, unflavoured powder with a suspension agent, and flavoured powder with a suspension agent. This study will be conducted in Dhaka, Bangladesh. This study hypothesizes that that the formulation of the delivery vehicle will impact preference, acceptability, and palatability.

Condition or Disease Intervention/Treatment Phase
  • Drug: Traditional Tablet
  • Drug: Chewable tablets
  • Drug: Unflavoured Powder
  • Drug: Flavoured Powder

Study Design

Study Type:
Observational
Actual Enrollment :
149 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Preference, Acceptability, and Palatability of Alternative Delivery Vehicles for Prenatal Calcium Supplementation Among Pregnant Women in Bangladesh
Study Start Date :
Oct 1, 2012
Actual Primary Completion Date :
Mar 1, 2013
Actual Study Completion Date :
Mar 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Pregnant Women

Women who are 13 to 30 weeks pregnant. Each participant will take all 4 different calcium vehicles and decide which one they prefer.

Drug: Traditional Tablet
The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.

Drug: Chewable tablets
Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.

Drug: Unflavoured Powder
The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.

Drug: Flavoured Powder
The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.

Outcome Measures

Primary Outcome Measures

  1. Frequency of Consumption of the Calcium Vehicle [Change from Baseline in Consumption of the Calcium Vehicle at day 22]

    Consumption of the delivery vehicles will be measured during the once-weekly interactions with the research assistants in two ways: (1) by self-report from study participants; and (2) by counting the number of missing doses from those provided in the weekly supply.

Secondary Outcome Measures

  1. Acceptability [Day 1, Day 9, Day 16, Day 22]

    Measured by colour, preparation, administration.

  2. Ease of Use [Day 1, Day 9, Day 16, Day 22]

    Measured by size and ease of swallowing.

  3. Patibility [Day 1, Day 9, Day 16, Day 22]

    Measured by taste, texture, aftertaste, and odour.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Pregnant women ages 18 to < 40 years

  • Gestational age of 13-30 completed weeks, estimated based on the recalled first day of the last menstrual period (LMP)

  • Current residence in Dhaka at a fixed address

  • Plan to remain in Dhaka for the duration of the study

Exclusion Criteria:
  • Reported complications of current pregnancy

  • Complicated medical or obstetric history that may increase the risk of preterm birth or prenatal complications, based on self-report

  • Moderate or severe anaemia (hemoglobin < 90 g/L, accessed with Hemocue)

Contacts and Locations

Locations

Site City State Country Postal Code
1 International Center for Diarrheal Disease Research Dhaka Bangladesh
2 The Hospital for Sick Children Toronto Ontario Canada M5G 1X8

Sponsors and Collaborators

  • The Hospital for Sick Children
  • The Sprinkles Global Health Initiative
  • International Centre for Diarrhoeal Disease Research, Bangladesh

Investigators

  • Principal Investigator: Stanley Zlotkin, MD, The Hospital for Sick Children
  • Principal Investigator: Daniel Roth, MD, The Hospital for Sick Children

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stanley Zlotkin, Chief, Global Child Health, The Hospital for Sick Children
ClinicalTrials.gov Identifier:
NCT01676636
Other Study ID Numbers:
  • 1000032744
First Posted:
Aug 31, 2012
Last Update Posted:
Apr 19, 2021
Last Verified:
Apr 1, 2021
Keywords provided by Stanley Zlotkin, Chief, Global Child Health, The Hospital for Sick Children

Study Results

No Results Posted as of Apr 19, 2021